Kerala's Decision to Rehabilitate a Controversial Drug Manufacturer: A Case Study in Due Process and Fairness
In a recent development, the Kerala government has taken a controversial decision to remove a drug manufacturer from its blacklist, citing the 'benefit of doubt'. The decision comes after a thorough investigation into a complaint alleging that a Paracetamol tablet contained a metal piece. The manufacturer, Healer's Lab, had faced severe consequences for this alleged issue, including a two-year blacklist sanction imposed by the Kerala Medical Services Corporation Ltd (KMSCL).
The controversy began when a patient at the Community Health Centre in Narikkuni, Kozhikode, reported a quality issue with the Paracetamol tablets supplied by Healer's Lab. The health department's internal inquiry confirmed the complaint, leading to the blacklist order. However, Healer's Lab challenged the decision in the High Court, arguing that the government failed to prove the tablet's origin and that the issue was a result of a warehouse manager's assessment.
The High Court's intervention was crucial, as it directed the government to provide a resolution within three months and allowed Healer's Lab to participate in tenders from other authorities. During the legal proceedings, the company presented evidence that it had supplied over 20 crore tablets without any reported quality issues since winning the bid in 2023-24. This raised doubts about the authenticity of the initial complaint.
The KMSCL, however, maintained that the complaint was verified by an official, who confirmed the presence of a foreign particle that could be metal. The State Drugs Controller's investigation further supported this, as the particle was radiopaque to X-rays, suggesting a metallic composition. Additionally, the Drugs Control Department reported several complaints regarding the same batch of Paracetamol tablets, leading to the declaration of 15 batches as Not of Standard Quality (NSQ).
Despite these findings, the government acknowledged that the verification process was limited to physical examination and X-ray imaging, without further quality analysis. The Medical Officer's delay in providing the evidence sample to KMSCL also raised concerns. The Health and Family Welfare department's order emphasized the need to consider the impact of blacklisting on the company's operations across India, as it denied participation in tenders in other states.
In the end, the government's decision to lift the blacklist order and allow Healer's Lab to continue its operations is a significant development. It highlights the importance of due process, fair investigation, and the 'benefit of doubt' in such cases. This case study serves as a reminder that even in the face of potential health risks, the legal and ethical standards must be upheld to ensure the integrity of the pharmaceutical industry.
